Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin.
The effectiveness of rifampicin (RIF), amikacin (AMK) and their combination were estimated in the treatment of mice experimentally infected by Mycobacterium ulcerans and the risk of relapse after the treatment was evaluated. After 7 weeks of treatment with RIF or with the combination of AMK/RIF and 8 weeks with AMK alone, no viable bacilli were found in the infected tissues and these remained uninfected during the following 6 months. Among the mice treated with AMK alone, three mice relapsed, but the minimal inhibitory concentration of AMK for these isolates remained unchanged. With RIF alone, two mice relapsed and the minimal inhibitory concentration of these isolated strains was higher. However, with all the mice treated with both RIF and AMK, no relapse was observed.
Marsollier
Laurent
L
Laboratoire de Bactériologie-Virologie-Hygiène Hospitalière, CHU, 49033 Angers Cedex 01, France.
Prévot
Ghislaine
G
Honoré
Nadine
N
Legras
Pierre
P
Manceau
Anne Lise
AL
Payan
Christopher
C
Kouakou
Henri
H
Carbonnelle
Bernard
B
D000583:Amikacin / Q000008:administration & dosage*; D000818:Animals; D015169:Colony Count, Microbial; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D008807:Mice, Inbred BALB C; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000382:microbiology; D019911:Mycobacterium ulcerans / Q000187:drug effects* / Q000302:isolation & purification; D012293:Rifampin / Q000008:administration & dosage*; D013997:Time Factors
D000583:Amikacin; D012293:Rifampin